Citius Oncology Net Income
| CTOR Stock | 1.15 0.04 3.60% |
As of the 10th of February, Citius Oncology shows the Mean Deviation of 4.36, risk adjusted performance of (0.03), and Standard Deviation of 6.34. Citius Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Oncology market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Citius Oncology is priced correctly, providing market reflects its regular price of 1.15 per share. Given that Citius Oncology is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Citius Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Citius Oncology's valuation are provided below:There are over ninety available fundamental signals for Citius Oncology, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Citius Oncology's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/10/2026, Market Cap is likely to drop to about 162.5 M. In addition to that, Enterprise Value is likely to drop to about 162.4 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -22.3 M | -23.4 M | |
| Net Loss | -22.3 M | -23.4 M | |
| Net Income Per E B T | 1.20 | 1.17 |
Citius | Net Income | Build AI portfolio with Citius Stock |
Evaluating Citius Oncology's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Citius Oncology's fundamental strength.
Latest Citius Oncology's Net Income Growth Pattern
Below is the plot of the Net Income of Citius Oncology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Citius Oncology financial statement analysis. It represents the amount of money remaining after all of Citius Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Citius Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Citius Oncology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Citius Net Income Regression Statistics
| Arithmetic Mean | (6,329,847) | |
| Coefficient Of Variation | (153.72) | |
| Mean Deviation | 8,284,038 | |
| Median | (10,113) | |
| Standard Deviation | 9,730,211 | |
| Sample Variance | 94.7T | |
| Range | 24.8M | |
| R-Value | (0.82) | |
| Mean Square Error | 32.7T | |
| R-Squared | 0.68 | |
| Significance | 0.000051 | |
| Slope | (1,584,386) | |
| Total Sum of Squares | 1514.8T |
Citius Net Income History
Other Fundumenentals of Citius Oncology
Citius Oncology Net Income component correlations
Citius Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Oncology is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Net Income. Since Citius Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Life Sciences Tools & Services industry sustain growth momentum? Does Citius have expansion opportunities? Factors like these will boost the valuation of Citius Oncology. Projected growth potential of Citius fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Citius Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Citius Oncology using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Citius Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Citius Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between Citius Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Citius Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Citius Oncology's market price signifies the transaction level at which participants voluntarily complete trades.
Citius Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Citius Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Citius Oncology.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Citius Oncology on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Citius Oncology or generate 0.0% return on investment in Citius Oncology over 90 days. Citius Oncology is related to or competes with Scilex Holding, Actuate Therapeutics, Forte Biosciences, Spero Therapeutics, Applied Therapeutics, Vor Biopharma, and Seres Therapeutics. Citius Oncology is entity of United States More
Citius Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Citius Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Citius Oncology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 40.44 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 8.73 |
Citius Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Citius Oncology's standard deviation. In reality, there are many statistical measures that can use Citius Oncology historical prices to predict the future Citius Oncology's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.44) |
Citius Oncology February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 4.36 | |||
| Coefficient Of Variation | (1,931) | |||
| Standard Deviation | 6.34 | |||
| Variance | 40.23 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 40.44 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 8.73 | |||
| Skewness | 0.6565 | |||
| Kurtosis | 3.68 |
Citius Oncology Backtested Returns
Citius Oncology secures Sharpe Ratio (or Efficiency) of -0.0159, which signifies that the company had a -0.0159 % return per unit of risk over the last 3 months. Citius Oncology exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Citius Oncology's Risk Adjusted Performance of (0.03), mean deviation of 4.36, and Standard Deviation of 6.34 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.76, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Citius Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Citius Oncology is expected to be smaller as well. At this point, Citius Oncology has a negative expected return of -0.1%. Please make sure to confirm Citius Oncology's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Citius Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.26 |
Weak reverse predictability
Citius Oncology has weak reverse predictability. Overlapping area represents the amount of predictability between Citius Oncology time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Citius Oncology price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current Citius Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Citius Income Before Tax
Income Before Tax |
|
Based on the recorded statements, Citius Oncology reported net income of (24.76 Million). This is much lower than that of the Life Sciences Tools & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Citius Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Oncology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Oncology could also be used in its relative valuation, which is a method of valuing Citius Oncology by comparing valuation metrics of similar companies.Citius Oncology is currently under evaluation in net income category among its peers.
Citius Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 99.63 M | ||||
| Shares Outstanding | 88.28 M | ||||
| Shares Owned By Insiders | 83.88 % | ||||
| Shares Owned By Institutions | 10.44 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Book | 2.22 X | ||||
| EBITDA | (23.49 M) | ||||
| Net Income | (24.76 M) | ||||
| Total Debt | 3.8 M | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (5.49 M) | ||||
| Short Ratio | 2.33 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 6.0 | ||||
| Beta | 3.1 | ||||
| Market Capitalization | 99.75 M | ||||
| Total Asset | 100.94 M | ||||
| Retained Earnings | (64.04 M) | ||||
| Working Capital | (21.95 M) | ||||
| Net Asset | 100.94 M |
About Citius Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Citius Stock
| 0.62 | FTRE | Fortrea Holdings | PairCorr |
| 0.59 | FIBK | First Interstate Ban | PairCorr |
| 0.58 | ENS | Enersys Earnings Call Tomorrow | PairCorr |
| 0.54 | YLLXF | Yellow Cake plc | PairCorr |
| 0.51 | SLF | Sun Life Financial Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Citius Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology to buy it.
The correlation of Citius Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.